Supplementary Materials

Supplementary Material for:

Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail

Boris Julg, Po-Ting Liu, Kshitij Wagh, William M. Fischer, Peter Abbink, Noe B. Mercado, James B. Whitney, Joseph P. Nkolola, Katherine McMahan, Lawrence J. Tartaglia, Erica N. Borducchi, Shreeya Khatiwada, Megha Kamath, Jake A. LeSuer, Michael S. Seaman, Stephen D. Schmidt, John R. Mascola, Dennis R. Burton, Bette T. Korber, Dan H. Barouch*

*Corresponding author. Email: dbarouch{at}bidmc.harvard.edu

Published 20 September 2017, Sci. Transl. Med. 9, eaao4235 (2017)
DOI: 10.1126/scitranslmed.aao4235

This PDF file includes:

  • Fig. S1. Analysis of SHIV env sequences in PGT121-treated animals.
  • Fig. S2. Complementarity of complete neutralization profiles of PGDM1400 and PGT121 against HIV-1.
  • Fig. S3. Serum concentration of PGDM1400 and PGT121 in antibody-treated animals by ELISA.
  • Fig. S4. Serum concentration of PGDM1400 and PGT121 in antibody-treated animals by TZM-bl NAb assays.
  • Fig. S5. Comparison of ELISA and TZM-bl neutralization assays for evaluating pharmacokinetics of PGDM1400 and PGT121.
  • Fig. S6. Protective efficacy as measured by SHIV-SF162P3–specific viral loads.
  • Fig. S7. Protective efficacy as measured by SHIV-325c–specific viral loads.
  • Fig. S8. Structural modeling of PGT121 and PGDM1400 contact sites.
  • Fig. S9. Clade diversity of key signature residues for PGDM1400.
  • Fig. S10. Clade diversity of key signature residues for PGT121.
  • Table S1. Intrapatient variation in key contact signatures for PGDM140 and PGT121.

[Download PDF]